The U.S. FDA has approved Encelto, an ocular insert that delivers sustained therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina. Encelto is the first treatment for Macular Telangiectasia type 2 (MacTel), a rare, progressive neurodegenerative disease of the retina that leads to central vision loss. Encelto is designed to slow the progression of MacTel. The approval was based on phase 3 trial data, which showed significant slowing of macular photoreceptor loss over 24 months. Encelto is expected to be available in the United States in June 2025.

Source: Retinal Physician